Cara Therapeutics (CARA)
(Real Time Quote from BATS)
$0.67 USD
0.00 (-0.24%)
Updated Apr 25, 2024 10:56 AM ET
3-Hold of 5 3
F Value D Growth A Momentum D VGM
Brokerage Reports
0 items in cart
Cara Therapeutics, Inc. [CARA]
Reports for Purchase
Showing records 21 - 40 ( 55 total )
Company: Cara Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Ideal Korsuva Partner Triples Down; Brings in Capital; Bolsters our Confidence in Commercial Potential; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Company: Cara Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
IV Korsuva on Track for 4Q NDA; Stock Undervalued on That Alone; Hangover From Oral CKD-aP Phase 2 Still Unwarranted
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Company: Cara Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
1Q20 Results; On Track for 2H IV Korsuva NDA; Oral Phase 2 Timeline Largely Intact Despite COVID; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Company: Cara Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
KALM-2 Phase 3 is an Unequivocal Win, in Our View.
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Company: Cara Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Market Shudders But We See Names to Outperform.
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department
Company: Cara Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Cara Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Phase 2 Shows Oral Korsuva Works; But Gives Street Little Comfort on Oral Phase 3 Risk
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Company: Cara Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
3Q19 Results; Expect Positive Oral Korsuva Phase 2 Data in a Month.
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Company: Cara Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
2Q19 KALM-2 Interim Powering Update Next Couple Months
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Company: Cara Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Oral Korsuva Phase 2 Enrolled; Confirmed Power Increases Confidence in Positive Results Like IV Korsuva; Raise to $31
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Company: Cara Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Positive KALM-1 Data in CDK-aP Bodes Extremely Well for KALM-2 and Eventual CKD-aP Approval; Raise Target to $28
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Company: Cara Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Keep Calm: Expect Positive KALM-1 Phase 3 Data Imminently; KALM-2 Interim Powering Analysis Also on Tap
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Company: Cara Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Confident in Positive Korsuva Pivotal Data Within 3 Months; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Company: Cara Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Positive Korsuva Interim Powering Look Should Provide Material Sentiment Boost; Expect Outperformance into 2Q19 Data
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Company: Cara Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
3Q18 Results; Plowing Forward With CKD-aP Phase 3s; First Pivotal Data in 1H19; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Company: Cara Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
2Q18 Results; Pruritus Programs on Plan; Funded Well Past Key Data; CMS Payment Proposal Should De-Risk Initial Uptake
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Company: Cara Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Surprising Positive Post-Op Pain Data Provides Some Upside Optionality; Raise to $26
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Company: Cara Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Premier Partnership Incrementally De-Risks IV Korsuva; Reiterate Buy and Raise to $24
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Company: Cara Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
1Q18 Results; Pruritus Pipeline Progressing on Plan
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Company: Cara Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
4Q17 Results; Pruritus Plans on Track; Pain Played Down; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O